Measuring hypertrophy in neonatal rat primary cardiomyocytes and human iPSC-derived cardiomyocytes

Kyla Bourque1, Cara Hawey1, Jace Jones-Tabah1

  • 1Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec H3G 1Y6, Canada.

Methods (San Diego, Calif.)
|December 21, 2021
PubMed

Insights

Cardiac hypertrophy, a thickening of the heart wall, can impair blood flow. This study reviews models for studying cardiac hypertrophy, including cell lines and stem cell-derived cardiomyocytes.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Stem Cell Research

Background:

  • Left ventricular hypertrophy is an adaptive response to increased cardiac workload, often seen in hypertension and coronary artery disease.
  • Cardiac hypertrophy can lead to myocardial stiffening, impairing systemic blood supply.
  • Understanding the molecular mechanisms of cardiac hypertrophy is crucial for developing therapeutic strategies.

Purpose of the Study:

  • To review existing in vitro and in vivo model systems used for studying cardiac hypertrophy.
  • To provide detailed methodologies for isolating primary neonatal rat cardiomyocytes and generating human induced pluripotent stem cell-derived cardiomyocytes.
  • To describe methods for modeling cardiac hypertrophy in vitro using advanced imaging and molecular analysis.

Main Methods:

  • Review of established in vitro (cell lines, iPSC-CMs) and in vivo (rodent, large animal) models.
  • Detailed protocols for primary neonatal rat cardiomyocyte isolation.
  • Generation of cardiomyocytes from human induced pluripotent stem cells (hiPSC-CMs).
  • In vitro modeling of hypertrophy using gene expression analysis, immunofluorescence, and high-content imaging.

Main Results:

  • Various model systems, including cell lines, animal models, and iPSC-CMs, have been instrumental in understanding cardiac hypertrophy.
  • Primary neonatal rat cardiomyocytes and hiPSC-CMs offer valuable platforms for mechanistic studies.
  • Integrated approaches combining molecular and imaging techniques enable robust in vitro hypertrophy modeling.

Conclusions:

  • A range of experimental models are available for investigating the molecular drivers of cardiac hypertrophy.
  • Human iPSC-derived cardiomyocytes provide a disease-relevant model for studying hypertrophic cardiomyopathies.
  • Standardized methods for cardiomyocyte isolation and in vitro hypertrophy modeling are essential for advancing research in this field.

Related Concept Videos